ANIP
ANI Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$71.20
−1.09%Year over year
Reported trailing growth
- Revenue
- +30.9%
- EBITDA
- +187.3%
- EBIT
- +888.7%
- EPS
- +744.0%
- Free cash flow
- +51.7%
- Operating cash flow
- +36.2%
Forward estimates
Based on analyst estimates
- Revenue
- +19.5%
- EBITDA
- +39.6%
- EPS
- +94.8%
Three-year CAGR
- Revenue
- +40.8%
- EBITDA
- +102.3%
- EBIT
- +31.5%
- Net income
- +104.2%
- EPS
- +91.9%
- Free cash flow
- +22.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026